Humana Inc. (NYSE:HUM) Shares Sold by Caprock Group LLC

Caprock Group LLC cut its stake in shares of Humana Inc. (NYSE:HUM) by 4.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,353 shares of the insurance provider’s stock after selling 68 shares during the quarter. Caprock Group LLC’s holdings in Humana were worth $621,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in HUM. Norges Bank acquired a new stake in Humana in the 4th quarter valued at about $690,516,000. Starboard Value LP acquired a new stake in Humana in the 1st quarter valued at about $421,332,000. Ameriprise Financial Inc. grew its stake in Humana by 35.9% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock valued at $741,409,000 after acquiring an additional 402,559 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in Humana in the 1st quarter valued at about $151,766,000. Finally, Morgan Stanley grew its stake in Humana by 20.8% in the 4th quarter. Morgan Stanley now owns 1,688,442 shares of the insurance provider’s stock valued at $864,804,000 after acquiring an additional 290,865 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Humana

In other Humana news, Director Jorge S. Mesquita purchased 545 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were purchased at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the acquisition, the director now owns 2,578 shares of the company’s stock, valued at approximately $946,358.02. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.32% of the stock is currently owned by insiders.

Humana Trading Down 0.8 %

Shares of HUM stock opened at $346.72 on Friday. The firm has a market cap of $41.83 billion, a P/E ratio of 17.49, a PEG ratio of 2.03 and a beta of 0.45. Humana Inc. has a 1-year low of $334.54 and a 1-year high of $541.21. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.59 and a quick ratio of 1.59. The firm’s 50-day simple moving average is $360.02 and its 200-day simple moving average is $441.14.

Humana (NYSE:HUM) last announced its quarterly earnings data on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.87). Humana had a return on equity of 19.44% and a net margin of 2.34%. The company had revenue of $26.46 billion for the quarter, compared to analysts’ expectations of $25.47 billion. During the same quarter in the previous year, the company earned $1.62 earnings per share. The company’s revenue was up 17.9% on a year-over-year basis. As a group, equities analysts forecast that Humana Inc. will post 16.04 EPS for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Friday, March 29th will be issued a $0.885 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $3.54 annualized dividend and a yield of 1.02%. Humana’s payout ratio is 17.86%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HUM. Wells Fargo & Company lowered their price objective on shares of Humana from $465.00 to $413.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 30th. Truist Financial reaffirmed a “hold” rating and set a $550.00 price target on shares of Humana in a research note on Friday, January 19th. Argus cut shares of Humana from a “buy” rating to a “hold” rating in a research note on Wednesday, March 13th. Stephens decreased their price target on shares of Humana from $550.00 to $430.00 and set an “overweight” rating on the stock in a research note on Friday, January 26th. Finally, Mizuho decreased their price target on shares of Humana from $550.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, January 26th. Ten research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Humana currently has a consensus rating of “Hold” and a consensus target price of $494.00.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.